Extracted from this filing and checked against the source text.
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.95
OMEROS CORP completed a disposition involving Novo Nordisk Health Care AG for upfront cash payment of $240.0 million at closing, plus potential milestone payments up to $1.81 billion (development and sales-based milestones) and tiered roy (closed 2025-11-25).
- Action
- disposition
- Counterparty
- Novo Nordisk Health Care AG
- Consideration
- upfront cash payment of $240.0 million at closing, plus potential milestone payments up to $1.81 billion (development and sales-based milestones) and tiered roy
- Closing
- 2025-11-25
Exact text from the filing
development and commercialization activities of both companies (the “Transaction”). At the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OMEROS CORP entered into Asset Purchase Agreement with Novo Nordisk valued at Upfront cash payment of $240 million, plus up to $510 million in development/approval milestones and (effective 2025-12-01).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Novo Nordisk
- Value
- Upfront cash payment of $240 million, plus up to $510 million in development/approval milestones and
- Effective
- 2025-12-01
Exact text from the filing
the closing of the Transaction (the “Closing”), Omeros received an upfront cash payment of $240.0 million, approximately $72.6 million of which was used to repay the Credit Agreement as described in Item 1.02 above. In addition, Omeros can receive (i) up to a total of $510 million in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of each of the development and approval milestone events as set forth in the Agreement and (ii) up to $1.3 billion in one-time milestone payments upon the first achievement by Novo Nordisk or its affiliates or sublicensees of certain sales-based milestone events as set forth in the Agreement. The upfront cash received at closing and the potential milestone payments represent a total of $2.1 billion.
View on SEC.gov